RAS Mutation: Clinical Trials

4 trials for RAS Mutation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Recruiting 4
Phase 12Recruiting 2

Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingGenfleet Therapeutics (Shanghai) Inc.2222026-09-012026-10-05
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingTango Therapeutics, Inc.1832025-05-312026-10-23
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
irinotecan, cetuximab, envafolimab - RAS Mutation, Metastatic Colorectal Cancer
Phase 2RecruitingBeijing Hospital602024-03-012026-07-28
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Cadonilimab + bevacizumab + FOLFOX - Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma
Phase 2RecruitingFudan University532024-01-012024-01-23

Narrower conditions

Colorectal Neoplasms (2)  ·  Lung Neoplasms (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Colonic Diseases (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Intestinal Diseases (2)  ·  Intestinal Neoplasms (2)  ·  Rectal Diseases (2)  ·  Lung Diseases (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)

Interventions

Cetuximab (2)  ·  Irinotecan (2)  ·  Bevacizumab (1)  ·  Fluorouracil (1)  ·  Folfox protocol (1)  ·  Gemcitabine (1)  ·  Immune Checkpoint Inhibitors (1)  ·  Leucovorin (1)  ·  Oxaliplatin (1)  ·  Taxes (1)  ·  envafolimab (1)

Sponsors

Beijing Hospital (1)  ·  Fudan University (1)  ·  Genfleet Therapeutics (Shanghai) Inc. (1)  ·  Tango Therapeutics, Inc. (1)

Countries

China (3)  ·  Australia (1)  ·  United States (1)

Top investigators

Maxim Pimpkin, MD, PhD (1)